News

Phase II data: Nexavar effective against further types of cancer

Hope for cancer patients: Bayer HealthCare employee David Milczanowski performs the filling process for the cancer drug Nexavar® at Bayer's facility in Wuppertal.

Zoom image

Hope for cancer patients: Bayer HealthCare employee David Milczanowski performs the filling process for the cancer drug Nexavar® at Bayer’s facility in Wuppertal.

Berlin/Chicago – New data show increased application potential for the cancer drug Nexavar®. Findings from the drug’s Phase II development program were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Tablets containing the active substance sorafenib are currently being tested in multiple tumor types including lung, thyroid, gastric and ovarian cancers.

Nexavar® is currently approved in more than 40 countries – now including China – for the treatment of patients with inoperable liver cancer and in more than 70 countries for the treatment of advanced kidney cancer.

Following the approval by the U.S. Food and Drug Administration of the contrast agent Primovist®, the company now supplies two products that complement each other in the diagnosis and therapy of liver cancer. Primovist® is now available in more than 40 countries for the diagnosis of liver diseases.